

Rekha Chaudhuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1440883/publications.pdf>

Version: 2024-02-01

40
papers

2,481
citations

361413

20
h-index

289244

40
g-index

40
all docs

40
docs citations

40
times ranked

2725
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.	6.7	8
2	Ethnic Differences in Severe Asthma Clinical Care and Outcomes: An Analysis of United Kingdom Primary and Specialist Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 495-505.e2.	3.8	14
3	The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. <i>ERJ Open Research</i> , 2022, 8, 00065-2022.	2.6	3
4	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	1.6	2
5	Exacerbation Profile and Risk Factors in a Type-2â€“Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	5.6	14
6	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarkerâ€“high and â€“low severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	5.7	11
7	Composite type-2 biomarker strategy versus a symptomâ€“risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 57-68.	10.7	88
8	Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 457-466.	10.7	63
9	Biologics in severe asthma: Which one, When and Where?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1225-1228.	2.9	5
10	Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy. <i>ERJ Open Research</i> , 2021, 7, 00273-2021.	2.6	5
11	Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2691-2701.e1.	3.8	13
12	Recommendations following a modified UK-Delphi consensus study on best practice for referral and management of severe asthma. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001057.	3.0	4
13	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 731-734.	5.6	40
14	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 1174-1184.	10.7	49
15	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.	2.6	14
16	Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatability. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101951.	2.6	2
17	5-Year Survival after Endobronchial Coil Implantation: Secondary Analysis of the First Randomised Controlled Trial, RESET. <i>Respiration</i> , 2020, 99, 154-162.	2.6	15
18	Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study. <i>Thorax</i> , 2019, 74, 806-809.	5.6	18

#	ARTICLE	IF	CITATIONS
19	Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 454-464.	5.6	115
20	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	2.8	7
21	<i>in vitro</i> , <i>in silico</i> and <i>in vivo</i> study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss. European Respiratory Journal, 2018, 51, 1701680.	6.7	42
22	Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths recommendations. Npj Primary Care Respiratory Medicine, 2018, 28, 35.	2.6	20
23	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.	7.4	67
24	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respiratory Medicine, 2018, 6, 499-510.	10.7	104
25	Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open, 2016, 6, e011857.	1.9	61
26	Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. Respiratory Medicine, 2016, 118, 46-52.	2.9	12
27	Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax, 2016, 71, 339-346.	5.6	257
28	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 2015, 16, 267.	1.6	20
29	Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life. Chest, 2015, 148, 870-876.	0.8	100
30	Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulmonary Pharmacology and Therapeutics, 2015, 31, 1-8.	2.6	29
31	The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 2015, 70, 376-378.	5.6	152
32	Effectiveness of bronchial thermoplasty in severe asthma in "real life" patients compared with those recruited to clinical trials in the same centre. Therapeutic Advances in Respiratory Disease, 2015, 9, 267-271.	2.6	28
33	Details of development of the resource for adults with asthma in the RAISON (randomized trial of an) Tj ETQq1 1 0.784314 rgBT /Overl... 2015, 15, 57.	3.0	21
34	Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability. PLoS ONE, 2014, 9, e102987.	2.5	94
35	Sputum matrix metalloproteinase-9 is associated with the degree of emphysema on computed tomography in COPD. Translational Respiratory Medicine, 2013, 1, 11.	3.8	16
36	Obesity-Associated Severe Asthma Represents a Distinct Clinical Phenotype. Chest, 2013, 143, 406-414.	0.8	109

#	ARTICLE	IF	CITATIONS
37	Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 655-663.e8.	2.9	90
38	Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 127-133.	5.6	271
39	Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1063-1070.	2.9	77
40	Cigarette Smoking Impairs the Therapeutic Response to Oral Corticosteroids in Chronic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1308-1311.	5.6	421